Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Co-Administration of Fish Oil With Signal Transduction Inhibitors Has Anti-Migration Effects in Breast Cancer Cell Lines, in vitro.

Davison Z, Nicholson RI, Hiscox S, Heard CM.

Open Biochem J. 2018 Aug 31;12:130-148. doi: 10.2174/1874091X01812010130. eCollection 2018.

2.

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JMW, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2018 Aug 30;20(1):98. doi: 10.1186/s13058-018-0999-6.

3.

The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.

Kandil S, Prencipe F, Jones S, Hiscox S, Westwell AD.

Chem Biol Drug Des. 2018 Jan;91(1):314-321. doi: 10.1111/cbdd.13083. Epub 2017 Aug 30.

PMID:
28816016
4.

The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.

Wymant JM, Hiscox S, Westwell AD, Urbé S, Clague MJ, Jones AT.

J Cancer. 2016 Dec 9;7(15):2388-2407. eCollection 2016.

5.

Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance.

Bellerby R, Smith C, Kyme S, Gee J, Günthert U, Green A, Rakha E, Barrett-Lee P, Hiscox S.

Front Oncol. 2016 Jun 20;6:145. doi: 10.3389/fonc.2016.00145. eCollection 2016.

6.

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.

Gangadhara S, Smith C, Barrett-Lee P, Hiscox S.

BMC Cancer. 2016 Jun 1;16:345. doi: 10.1186/s12885-016-2377-z.

7.

Computer-aided identification of novel anticancer compounds with a possible dual HER1/HER2 inhibition mechanism.

Elseginy SA, Lazaro G, Nawwar GA, Amin KM, Hiscox S, Brancale A.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):758-62. doi: 10.1016/j.bmcl.2014.12.095. Epub 2015 Jan 6.

PMID:
25619636
8.

Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells.

Wiggins HL, Wymant JM, Solfa F, Hiscox SE, Taylor KM, Westwell AD, Jones AT.

Biochem Pharmacol. 2015 Feb 1;93(3):332-42. doi: 10.1016/j.bcp.2014.12.014. Epub 2014 Dec 31.

9.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

10.
11.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

PMID:
23900794
12.

Pro-metastatic tumor-stroma interactions in breast cancer.

Gangadhara S, Barrett-Lee P, Nicholson RI, Hiscox S.

Future Oncol. 2012 Nov;8(11):1427-42. doi: 10.2217/fon.12.134. Review.

PMID:
23148616
13.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.

BMC Cancer. 2012 Oct 6;12:458. doi: 10.1186/1471-2407-12-458.

14.

Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.

Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P.

Sci Signal. 2012 Feb 7;5(210):ra11. doi: 10.1126/scisignal.2002585.

15.

Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer.

Hiscox S, Nicholson RI.

Expert Rev Endocrinol Metab. 2011 May;6(3):423-435. doi: 10.1586/eem.11.29.

PMID:
30754115
16.

Therapeutic targeting of tumor-stroma interactions.

Hiscox S, Barrett-Lee P, Nicholson RI.

Expert Opin Ther Targets. 2011 May;15(5):609-21. doi: 10.1517/14728222.2011.561201. Epub 2011 Mar 10. Review.

PMID:
21388336
17.

Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.

Gee JM, Nicholson RI, Barrow D, Dutkowski CM, Goddard L, Jordan NJ, McClelland RA, Knowlden JM, Francies HE, Hiscox SE, Hutcheson IR.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(2):67-77. doi: 10.1515/HMBCI.2011.009.

PMID:
25961242
18.

Acquired endocrine resistance in breast cancer: implications for tumour metastasis.

Hayes E, Nicholson RI, Hiscox S.

Front Biosci (Landmark Ed). 2011 Jan 1;16:838-48. Review.

PMID:
21196206
19.

New therapeutic approaches in breast cancer.

Davies E, Hiscox S.

Maturitas. 2011 Feb;68(2):121-8. doi: 10.1016/j.maturitas.2010.10.012. Epub 2010 Dec 8. Review.

PMID:
21144683
20.

Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration.

Weaver BP, Zhang Y, Hiscox S, Guo GL, Apte U, Taylor KM, Sheline CT, Wang L, Andrews GK.

PLoS One. 2010 Oct 4;5(10). pii: e13158. doi: 10.1371/journal.pone.0013158.

21.

Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention.

Wadhawan A, Smith C, Nicholson RI, Barrett-Lee P, Hiscox S.

Cancer Treat Rev. 2011 May;37(3):234-41. doi: 10.1016/j.ctrv.2010.08.003. Review.

PMID:
20888696
22.

Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.

Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI.

Eur J Cancer. 2010 Aug;46(12):2187-95. doi: 10.1016/j.ejca.2010.04.012. Epub 2010 May 13. Review.

PMID:
20471823
23.

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI, Barrett-Lee P.

Breast Cancer Res Treat. 2011 Feb;125(3):659-69. doi: 10.1007/s10549-010-0857-4. Epub 2010 Mar 31.

PMID:
20354780
24.

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.

Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S.

Cancer Biol Ther. 2009 Aug;8(16):1550-8.

PMID:
19830888
25.

Aromatase inhibitors in breast cancer.

Hiscox S, Davies EL, Barrett-Lee P.

Maturitas. 2009 Aug 20;63(4):275-9. doi: 10.1016/j.maturitas.2009.05.008. Epub 2009 Jul 3. Review.

PMID:
19577386
26.

SRC as a therapeutic target in breast cancer.

Morgan L, Nicholson RI, Hiscox S.

Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):273-8. Review.

PMID:
19075780
27.

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI.

Breast Cancer Res. 2008;10(6):R103. doi: 10.1186/bcr2206. Epub 2008 Dec 4.

28.

ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.

Taylor KM, Vichova P, Jordan N, Hiscox S, Hendley R, Nicholson RI.

Endocrinology. 2008 Oct;149(10):4912-20. doi: 10.1210/en.2008-0351. Epub 2008 Jun 26.

PMID:
18583420
29.

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI.

Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21.

PMID:
18493848
30.

Src inhibitors in breast cancer therapy.

Hiscox S, Nicholson RI.

Expert Opin Ther Targets. 2008 Jun;12(6):757-67. doi: 10.1517/14728222.12.6.757 . Review.

PMID:
18479222
31.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50. Erratum in: Breast Cancer Res. 2018 Aug 30;20(1):98.

32.

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM.

Rev Endocr Metab Disord. 2007 Sep;8(3):241-53. Review.

PMID:
17486454
33.

Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.

Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI.

Clin Exp Metastasis. 2007;24(3):157-67. Epub 2007 Mar 30.

PMID:
17394086
34.

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.

Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S77-88. Review.

PMID:
17259561
35.

Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.

Hiscox S, Morgan L, Green T, Nicholson RI.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S53-9. Review.

PMID:
17259559
36.

Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI.

Endocr Relat Cancer. 2006 Dec;13(4):1085-99.

PMID:
17158755
37.

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI.

Breast Cancer Res Treat. 2006 Jun;97(3):263-74. Epub 2005 Dec 7.

PMID:
16333527
38.

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S29-36. Review.

PMID:
16113097
39.

Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.

Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, Barrow D, Nicholson RI.

Int J Cancer. 2006 Jan 15;118(2):290-301.

40.

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.

Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):257-62. Epub 2005 Feb 8. Review.

PMID:
15860268
41.

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI.

Endocr Relat Cancer. 2004 Dec;11(4):793-814.

PMID:
15613453
42.

Zinc transporter LIV-1: a link between cellular development and cancer progression.

Taylor KM, Hiscox S, Nicholson RI.

Trends Endocrinol Metab. 2004 Dec;15(10):461-3.

PMID:
15541644
43.

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI.

Clin Exp Metastasis. 2004;21(3):201-12.

PMID:
15387370
44.

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S.

45.

GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface.

Hiscox S, Hallett MB, Morgan BP, van den Berg CW.

Biochem Biophys Res Commun. 2002 May 3;293(2):714-21.

PMID:
12054528
46.

Phenotypic variation in the production of bioactive hepatocyte growth factor/scatter factor by oral mucosal and skin fibroblasts.

Stephens P, Hiscox S, Cook H, Jiang WG, Zhiquiang W, Thomas DW.

Wound Repair Regen. 2001 Jan-Feb;9(1):34-43.

PMID:
11350638
47.

Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.

Hiscox S, Parr C, Nakamura T, Matsumoto K, Mansel RE, Jiang WG.

Breast Cancer Res Treat. 2000 Feb;59(3):245-54.

PMID:
10832594
48.

Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity.

Stead P, Hiscox S, Robinson PS, Pike NB, Sidebottom PJ, Roberts AD, Taylor NL, Wright AE, Pomponi SA, Langley D.

Bioorg Med Chem Lett. 2000 Apr 3;10(7):661-4.

PMID:
10762048
49.

Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells.

Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG.

Int J Cancer. 2000 Feb 15;85(4):563-70.

50.

Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.

Jiang WG, Hiscox SE, Parr C, Martin TA, Matsumoto K, Nakamura T, Mansel RE.

Clin Cancer Res. 1999 Nov;5(11):3695-703.

Supplemental Content

Loading ...
Support Center